Results 51 to 60 of about 19,745 (243)

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

Hematological Oncology, Volume 40, Issue 5, Page 987-998, December 2022., 2022
Abstract The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or immunomodulatory drugs +/− the monoclonal antibody Daratumumab are used for first‐line treatment, even if head‐to‐head comparisons are lacking.
Cirino Botta, Emilia Gigliotta, Bruno Paiva, Rita Anselmo, Marco Santoro, Paula Rodriguez Otero, Melania Carlisi, Concetta Conticello, Alessandra Romano, Antonio Giovanni Solimando, Claudio Cerchione, Matteo Da Vià, Niccolò Bolli, Pierpaolo Correale, Francesco Di Raimondo, Massimo Gentile, Jesus San Miguel, Sergio Siragusa   +17 more
wiley   +1 more source

Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds

Antibodies, 2018
Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not achievable with conventional monoclonal antibodies (mAbs).
Lilach Vaks, Dana Litvak-Greenfeld, Stav Dror, LeeRon Shefet-Carasso, Galia Matatov, Limor Nahary, Shiran Shapira, Rahely Hakim, Iris Alroy, Itai Benhar   +9 more
doaj   +1 more source

Autologous Peripheral Vγ9Vδ2 T Cell Synergizes with αβ T Cell Through Antigen Presentation and BTN3A1 Blockade in Immunotherapy of Cervical Cancer

Advanced Science, EarlyView.
This study provides proof‐of‐concept evidence showing that through direct killing, antigen presentation, and competitively binding to BTN3A1, Vγ9Vδ2 T cells amplified from cervical cancer (CC) patients can synergize with αβ T cells to exert anti‐CC function both in vitro and in vivo.
Min Wu, Jian Liu, Liting Liu, Yifan Yang, Hong Liu, Long Yu, Haihong Zeng, Shuo Yuan, Ruiyi Xu, Hangyu Liu, Han Jiang, Shen Qu, Liming Wang, Ying Chen, Jingyu Wang, Yuwei Zhang, Shan He, Ling Feng, Junyan Han, Wanjiang Zeng, Hui Wang, Yafei Huang   +21 more
wiley   +1 more source

Conditional Activation of Protein Therapeutics by Templated Removal of Peptide Nucleic Acid Masking Groups

Angewandte Chemie, EarlyView.
A strategy for the conditional activation of therapeutic proteins utilizing removable peptide nucleic acid (PNA) masking groups is presented. Site‐specific installation of “Lock”‐PNAs containing a cleavage thioester linkage enabled steric blockage of receptor binding sites.
Bengt H. Gless, Elisabeth Jones, Carlos Labão‐Almeida, Cong Tang, Nicole Gottscheber, Renata Couto, Gonçalo J. L. Bernardes   +6 more
wiley   +2 more sources

Intein mediated high throughput screening for bispecific antibodies

mAbs, 2020
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann, Johannes Schmidt, Elke Ciesielski, Stefan Becker, Thomas Rysiok, Mark Schütte, Lars Toleikis, Harald Kolmar, Achim Doerner   +8 more
doaj   +1 more source

GRP78 Nanobody‐Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy

Advanced Science, EarlyView.
A GRP78 nanobody‐directed immunotoxin suppresses cancer progression and metastasis by enhancing antitumor immunity via STING pathway activation, offering a pan‐cancer‐targeted approach and immunotherapy combination strategy. Abstract The lack of targetable antigens poses a significant challenge in developing effective cancer‐targeted therapies.
Huifang Wang, Runhua Zhou, Chengchao Xu, Lingyun Dai, Rui Hou, Liuhai Zheng, Chunjin Fu, Guangwei Shi, Jingwei Wang, Yang Li, Jinpeng Cen, Xiaolong Xu, Le Yu, Yilei Li, Jigang Wang, Qingfeng Du, Zhijie Li   +16 more
wiley   +1 more source

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

Antibodies, 2015
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies ...
Joanie Del Bano, Patrick Chames, Daniel Baty, Brigitte Kerfelec   +3 more
doaj   +1 more source

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

mAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero, Katharina B. Kroell, Lukas J. Grunewald, Anna-Lena M. Fischer, Jakob R. Riccabona, Klaus R. Liedl   +5 more
doaj   +1 more source

Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody [PDF]

, 2020
Broadly neutralizing antibodies are promising candidates for treatment and prevention of HIV-1 infections. Such antibodies can temporarily suppress viral load in infected individuals; however, the virus often rebounds by escape mutants that have evolved resistance.
arxiv   +1 more source

Bioorthogonal Reaction of o‐Quinone with Furan‐2(3H)‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes

Advanced Science, EarlyView.
A site‐selective, efficient, and mild tyrosine conjugation via tyrosinase oxidation and nucleophilic addition, allowing for site‐selective functionalization of peptides, recombinant proteins, and IgGs. Site‐selective mono‐functionalization of IgGs at Y296 enables the construction of immunoliposomes.
Hongfei Chen, Zhiyi Xu, Yishu Bao, Farshad Shiri, Dingdong Yuan, Yuke Hu, Biquan Li, Bin Zeng, Xiaojing Li, Hao Kong, Zikang Wang, Wilson Chun‐Yu Lau, Zhenyang Lin, Jiang Xia   +13 more
wiley   +1 more source